Literature DB >> 17956152

Weight gain with atypical antipsychotics: evidence and insights.

David C Henderson1.   

Abstract

Weight gain associated with antipsychotic medication can be a barrier to the overall improvement of mental health patients due to a discontinuation of treatment. The goal of this article is to establish a better understanding regarding the mechanisms of antipsychotic medications and their associated risk of weight gain, obesity, and subsequent mortality and morbidity. Additionally, the need to closely monitor patients' lifestyles and homeostatic components in order to prevent weight gain or facilitate weight loss is emphasized.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956152

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

1.  A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.

Authors:  Benjamin U Nwosu; Bruce Meltzer; Louise Maranda; Carol Ciccarelli; Daniel Reynolds; Laura Curtis; Jean King; Jean A Frazier; Mary M Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

2.  Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation.

Authors:  E A Hackler; N E Byun; C K Jones; J M Williams; R Baheza; S Sengupta; M D Grier; M Avison; P J Conn; J C Gore
Journal:  Neuroscience       Date:  2010-03-27       Impact factor: 3.590

3.  Effect of a motivational intervention on exercise behavior in persons with schizophrenia spectrum disorders.

Authors:  Lora Humphrey Beebe; Kathy Smith; Renee Burk; Kelly McIntyre; Olivera Dessieux; Abbas Tavakoli; Clif Tennison; Dawn Velligan
Journal:  Community Ment Health J       Date:  2010-11-27

4.  Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine.

Authors:  Shaunna L Clark; Daniel E Adkins; Edwin J C G van den Oord
Journal:  Schizophr Res       Date:  2011-08-27       Impact factor: 4.939

5.  Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity.

Authors:  Robert K McNamara; Ronald Jandacek; Therese Rider; Patrick Tso; Allyson Cole-Strauss; Jack W Lipton
Journal:  Schizophr Res       Date:  2011-04-07       Impact factor: 4.939

6.  Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase.

Authors:  Robert K McNamara; I Jack Magrisso; Rylon Hofacer; Ronald Jandacek; Therese Rider; Patrick Tso; Stephen C Benoit
Journal:  Pharmacol Res       Date:  2012-06-29       Impact factor: 7.658

7.  Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.

Authors:  Jian-Jun Ou; Yi Xu; Hong-Hui Chen; Xiaoduo Fan; Keming Gao; Juan Wang; Xiao-Feng Guo; Ren-Rong Wu; Jing-Ping Zhao
Journal:  Psychopharmacology (Berl)       Date:  2012-08-28       Impact factor: 4.530

8.  The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Authors:  Esther Garcia; Marta Robert; Francesc Peris; Hiroshi Nakamura; Noriko Sato; Yoshikatsu Terazawa
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Changes in body weight and psychotropic drugs: a systematic synthesis of the literature.

Authors:  Robert Dent; Angelique Blackmore; Joan Peterson; Rami Habib; Gary Peter Kay; Alan Gervais; Valerie Taylor; George Wells
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

10.  Adult medication-free schizophrenic patients exhibit long-chain omega-3 Fatty Acid deficiency: implications for cardiovascular disease risk.

Authors:  Robert K McNamara; Ronald Jandacek; Therese Rider; Patrick Tso; Yogesh Dwivedi; Ghanshyam N Pandey
Journal:  Cardiovasc Psychiatry Neurol       Date:  2013-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.